Summary
The claims align with the label for ipilimumab as the active ingredient and its indication for unresectable or metastatic melanoma; however, the wording suggesting 'certain types of skin cancer' is not fully supported by the labeled indication.
Category Scores
Accurate Statements
YERVOY is ipilimumab.
Label identifies the brand YERVOY and the active ingredient ipilimumab in DESCRIPTION.
Ipilimumab is indicated for unresectable or metastatic melanoma.
LABEL Section 1.1 UNRESECTABLE OR METASTATIC MELANOMA.
Unsupported Statements
Ipilimumab is used to treat certain types of skin cancer other than melanoma.
Label only specifies unresectable or metastatic melanoma; other skin cancers are not indicated in the cited sections.
Contradictions
Important Omissions
Did not specify that indications include adults and pediatric patients 12 years and older, nor that combination with nivolumab is permissible in some settings.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Evaluation focuses on label alignment; no safety claims introduced beyond what is in the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Ambiguity in the second claim regarding non-melanoma skin cancers; clarify indication to unresectable/metastatic melanoma only and mention pediatric age range and combination therapy as applicable.
Suggested Improvement
Reword claims to: 'YERVOY (ipilimumab) is indicated for unresectable or metastatic melanoma in adults and children 12 years and older, and may be used in combination with nivolumab.'